|Classification and external resources|
Thyroid cancer is a cancer originating from follicular or parafollicular thyroid cells. These cells give rise to both well-differentiated cancers (i.e., papillary and follicular) and anaplastic thyroid cancer. The second cell type, the C or parafollicular cell, produces the hormone calcitonin and is the cell of origin for medullary thyroid carcinoma (MTC).
The most effective management of aggressive thyroid cancers is surgical removal of thyroid gland (thyroidectomy) followed by radioactive iodine ablation and TSH-suppression therapy. Chemotherapy or radiotherapy may also be used in cases of distant metastases or advanced cancer stage. Five year survival rates are 97.8% in the United States.
Signs and symptoms
Most often the first symptom of thyroid cancer is a nodule in the thyroid region of the neck. However, many adults have small nodules in their thyroids, but typically under 5% of these nodules are found to be cancerous. Sometimes the first sign is an enlarged lymph node. Later symptoms that can be present are pain in the anterior region of the neck and changes in voice due to an involvement of the recurrent laryngeal nerve.
Thyroid nodules are of particular concern when they are found in those under the age of 20. The presentation of benign nodules at this age is less likely, and thus the potential for malignancy is far greater.
Thyroid cancers are thought to be related to a number of environmental and genetic predisposing factors, but significant uncertainty remains regarding its causes.
Environmental exposure to ionizing radiation from both natural background sources and artificial sources is suspected to play a significant role, and there are significant increased rates of thyroid cancer in those exposed to mantlefield radiation for lymphoma, and those exposed to iodine-131 following the Chernobyl disaster. Thyroiditis and other thyroid diseases also predispose to thyroid cancer.
After a thyroid nodule is found during a physical examination, a referral to an endocrinologist or a thyroidologist may occur. Most commonly an ultrasound is performed to confirm the presence of a nodule and assess the status of the whole gland. Measurement of thyroid stimulating hormone and anti-thyroid antibodies will help decide if there is a functional thyroid disease such as Hashimoto's thyroiditis present, a known cause of a benign nodular goiter. Measurement of calcitonin is necessary to exclude the presence of medullary thyroid cancer. Finally, to achieve a definitive diagnosis before deciding on treatment, a fine needle aspiration cytology test is usually performed and reported according to the Bethesda system.
Thyroid cancers can be classified according to their histopathological characteristics. The following variants can be distinguished (distribution over various subtypes may show regional variation):
- Papillary thyroid cancer (75% to 85% of cases) – often in young females – excellent prognosis. May occur in women with familial adenomatous polyposis and in patients with Cowden syndrome.
- Follicular thyroid cancer (10% to 20% of cases); occasionally seen in patients with Cowden syndrome
- Medullary thyroid cancer (5% to 8% of cases)- cancer of the parafollicular cells, often part of multiple endocrine neoplasia type 2.
- Poorly differentiated thyroid cancer
- Anaplastic thyroid cancer (less than 5% of cases) is not responsive to treatment and can cause pressure symptoms.
- Papillary microcarcinoma is a subset of papillary thyroid cancer defined as measuring less than or equal to 1 cm. The highest incidence of papillary thyroid microcarcinoma in autopsy series was reported by Harach et al. in 1985, who found 36 of 101 consecutive autopsies were found to have an incidental microcarcinoma. Michael Pakdaman et al. report the highest incidence in a retrospective surgical series at 49.9% of 860 cases. Management strategies for incidental papillary microcarcinoma on ultrasound (and confirmed on FNAB) range from total thyroidectomy with radioactive iodine ablation to observation alone. Harach et al. suggest using the term "occult papillary tumor" to avoid giving patients distress over having cancer. It was Woolner et al. who first arbitrarily coined the term "occult papillary carcinoma" in 1960, to describe papillary carcinomas ≤ 1.5 cm in diameter.
Thyroidectomy and dissection of central neck compartment is initial step in treatment of thyroid cancer in majority of cases. Thyroid-preserving operation may be applied in cases, when thyroid cancer exhibits low biological aggressiveness (e.g. well-differentiated cancer, no evidence of lymph node metastases, low MIB-1 index, no major genetic alterations like BRAF mutations, RET/PTC rearrangements, p53 mutations etc.) in patients younger than 45 years. If the diagnosis of well-differentiated thyroid cancer (e.g. papillary thyroid cancer) is established or suspected by FNA the surgery is indicated, whereas watchful waiting strategy is not recommended in any evidence-based guidelines. Watchful waiting reduces overdiagnosis and overtreatment of thyroid cancer among old patients. Radioactive Iodine-131 is used in patients with papillary or follicular thyroid cancer for ablation of residual thyroid tissue after surgery and for the treatment of thyroid cancer. Patients with medullary, anaplastic, and most Hurthle cell cancers do not benefit from this therapy.
Sorafenib and sunitinib, approved for other indications show promise for thyroid cancer and are being used for some patients who do not qualify for clinical trials. Numerous agents are in phase II clinical trials and XL184 has started a phase III trial.
|This section needs additional citations for verification. (October 2014)|
The prognosis of thyroid cancer is related to the type of cancer and the stage at the time of diagnosis. For the most common form of thyroid cancer, papillary, the overall prognosis is excellent. Indeed, the increased incidence of papillary thyroid carcinoma in recent years is likely related to increased and earlier diagnosis. One can look at the trend to earlier diagnosis in two ways. The first is that many of these cancers are small and not likely to develop into aggressive malignancies. A second perspective is that earlier diagnosis removes these cancers at a time when they are not likely to have spread beyond the thyroid gland, thereby improving the long-term outcome for the patient. There is no consensus at present on whether this trend toward earlier diagnosis is beneficial or unnecessary.
The argument against early diagnosis and treatment is based on the logic that many small thyroid cancers (mostly papillary) will not grow or metastasize. This viewpoint holds the overwhelming majority of thyroid cancers are overdiagnosed (that is, will never cause any symptoms, illness, or death for the patient, even if nothing is ever done about the cancer). Including these overdiagnosed cases skews the statistics by lumping clinically significant cases in with apparently harmless cancers. Thyroid cancer is incredibly common, with autopsy studies of people dying from other causes showing that more than one third of older adults technically has thyroid cancer, which is causing them no harm. It is easy to detect nodules that might be cancerous, simply by feeling the throat, which contributes to the level of overdiagnosis. Benign (non-cancerous) nodules frequently co-exist with thyroid cancer; sometimes, it is a benign nodule that is discovered but surgery uncovers an incidental small thyroid cancer. Increasingly, small thyroid nodules are discovered as incidental findings on imaging (CT scan, MRI, ultrasound) performed for another purpose ; very few of these people with accidentally discovered, symptom-free thyroid cancers will ever have any symptoms, and treatment in such patients has the potential to cause harm to them, not to help them.
Thyroid cancer is three times more common in women than in men, but according to European statistics, the overall relative 5-year survival rate for thyroid cancer is 85% for females and 74% for males.
The table below highlights some of the challenges with decision making and prognostication in thyroid cancer. While there is general agreement that stage I or II papillary, follicular or medullary cancer have a good prognosis, it is not possible when evaluating a small thyroid cancer to determine which ones will grow and metastasize and which will not. As a result once a diagnosis of thyroid cancer has been established (most commonly by a fine needle aspiration), it is likely that a total thyroidectomy will be performed.
This drive to earlier diagnosis has also manifest itself on the European continent by the use of serum calcitonin measurements in patients with goiter to identify patients with early abnormalities of the parafollicular or calcitonin-producing cells within the thyroid gland. As multiple studies have demonstrated, the finding of an elevated serum calcitonin is associated with the finding of a medullary thyroid carcinoma in as high as 20% of cases.
In Europe where the threshold for thyroid surgery is lower than in the United States, an elaborate strategy that incorporates serum calcitonin measurements and stimulatory tests for calcitonin has been incorporated into the decision to perform a thyroidectomy; thyroid experts in the USA, looking at the same data sets have, for the most part, not incorporated calcitonin testing as a routine part of their evaluation, thereby eliminating a large number of thyroidectomies and the consequent morbidity. The European thyroid community has focused on prevention of metastasis from small medullary thyroid carcinomas; the North American thyroid community has focused more on prevention of complications associated with thyroidectomy (see American Thyroid Association guidelines below). It is not clear at this time who is correct.
As demonstrated in the Table below, individuals with stage III and IV disease have a significant risk of dying from thyroid cancer. While many present with widely metastatic disease, an equal number evolve over years and decades from stage I or II disease. Physicians who manage thyroid cancer of any stage recognize that a small percentage of patients with low-risk thyroid cancer will progress to metastatic disease.
Fortunately for those with metastatic thyroid cancer, the last 5 years has brought about a renaissance in thyroid cancer treatment. The identification of some of the molecular or DNA abnormalities for thyroid cancer has led to the development of therapies that target these molecular defects. The first of these agents to negotiate the approval process is vandetanib, a tyrosine kinase inhibitor that targets the RET proto-oncogene, 2 subtypes of the vascular endothelial growth factor receptor, and the epidermal growth factor receptor. More of these compounds are under investigation and are likely to make it through the approval process. For differentiated thyroid carcinoma, strategies are evolving to use selected types of targeted therapy to increase radioactive iodine uptake in papillary thyroid carcinomas that have lost the ability to concentrate iodide. This strategy would make it possible to use radioactive iodine therapy to treat "resistant" thyroid cancers. Other targeted therapies are being evaluated, making it possible that life will be extended over the next 5–10 years for those with stage III and IV thyroid cancer.
Prognosis is better in younger people than older ones.
Prognosis depends mainly on the type of cancer and cancer stage.
Thyroid cancer type
|5-year survival||10-year survival|
|Stage I||Stage II||Stage III||Stage IV||Overall||Overall|
|Papillary||100%||100%||93%||51%||96% or 97%||93%|
|Medullary||100%||98%||81%||28%||80%, 83% or 86%||75%|
|Anaplastic||(always stage IV)||7%||7% or 14%||(no data)|
Thyroid cancer, in 2010, resulted in 36,000 deaths globally up from 24,000 in 1990. Obesity may be associated with a higher incidence of thyroid cancer, but this relationship remains the subject of much debate.
Thyroid cancer accounts for less than 1% of cancer cases and deaths in the UK. Around 2,700 people were diagnosed with Thyroid cancer in the UK in 2011, and around 370 people died from the disease in 2012.
- Daniel Snyder, American owner of the Washington Redskins football team
- Jerry Dipoto, former Major League Baseball pitcher.
- William Rehnquist, Chief Justice of the United States (1986-2005) died September 3, 2005 from anaplastic thyroid cancer
- Potassium iodide
- Thyroid neoplasm
- Thyroid nodule
- Medullary thyroid carcinoma
- Papillary thyroid carcinoma
- Follicular thyroid carcinoma
- Anaplastic thyroid carcinoma
- Carling, T.; Udelsman, R. (2014). "Thyroid Cancer". Annual Review of Medicine 65: 125–137. doi:10.1146/annurev-med-061512-105739.
- "SEER Stat Fact Sheets: Thyroid Cancer". NCI. Retrieved 18 June 2014.
- Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont JP. "Thyroid and Parathyroid Cancers" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
- "Radioactive I-131 from Fallout". National Cancer Institute. Retrieved 9 June 2014.
- Pacini, F. (2012). "Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology 21: 214–219. doi:10.1093/annonc/mdq190.
- "Genetics of Endocrine and Neuroendocrine Neoplasias". National Cancer Institute. Retrieved 9 June 2014.
- Bennedbaek FN, Perrild H, Hegedüs L (1999). "Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey". Clin. Endocrinol. (Oxf) 50 (3): 357–63. doi:10.1046/j.1365-2265.1999.00663.x. PMID 10435062.
- "Thyroid Cancer Treatment – National Cancer Institute". Retrieved 2007-12-22.
- "Thyroid cancer". Retrieved 2007-12-22.
- Chapter 20 in: Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. Robbins Basic Pathology. Philadelphia: Saunders. ISBN 1-4160-2973-7. 8th edition.
- Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M (2008). "New therapeutic approaches to treat medullary thyroid carcinoma". Nat Clin Pract Endocrinol Metab 4 (1): 22–32. doi:10.1038/ncpendmet0717. PMID 18084343.
- Nix P, Nicolaides A, Coatesworth AP (2005). "Thyroid cancer review 2: management of differentiated thyroid cancers". Int. J. Clin. Pract. 59 (12): 1459–63. doi:10.1111/j.1368-5031.2005.00672.x. PMID 16351679.
- Nix PA, Nicolaides A, Coatesworth AP (2006). "Thyroid cancer review 3: management of medullary and undifferentiated thyroid cancer". Int. J. Clin. Pract. 60 (1): 80–4. doi:10.1111/j.1742-1241.2005.00673.x. PMID 16409432.
- Shaha AR (2007). "TNM classification of thyroid carcinoma.". World J Surg 31 (5): 879–87. doi:10.1007/s00268-006-0864-0. PMID 17308849.
- Harach HR, Franssila KO, Wasenius VM (1985). "Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study.". Cancer 56 (3): 531–8. doi:10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3. PMID 2408737.
- Pakdaman MN, Rochon L, Gologan O, Tamilia M, Garfield N, Hier MP, Black MJ, Payne RJ (2008). "Incidence and histopathological behavior of papillary microcarcinomas: Study of 429 cases.". Otolaryngol Head Neck Surg 139 (5): 718–22. doi:10.1016/j.otohns.2008.08.014. PMID 18984270.
- Woolner LL, Lemmon ML, Beahrs OH, Black BM, Keating FR (1960). "Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period". J. Clin. Endocrinol. Metab. 20: 89–105. doi:10.1210/jcem-20-1-89. PMID 13845950.
- Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M, Sarfati E, Moretti JL, Bouchard P, Toubert ME (2007). "Bone metastases of differentiated thyroid cancer: Impact of early 131I-based detection on outcome". Endocrine-Related Cancer (Bioscientifica) 14 (3): 799–807. doi:10.1677/ERC-07-0120. PMID 17914109.
- Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C (1988). "Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays". Journal of nuclear medicine 29 (11): 1790–1794. PMID 3183748.
- Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009). "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.". Thyroid 19 (11): 1167–214. doi:10.1089/thy.2009.0110. PMID 19860577.
- British Thyroid Association, Royal College of Physicians, Perros P (2007). Guidelines for the management of thyroid cancer. 2nd edition. Report of the Thyroid Cancer Guidelines Update Group (PDF). Royal College of Physicians. p. 16. ISBN 9781860163098.
- Welch, H. Gilbert; Schwartz, Lisa; M.D., Lisa M. Schwartz,; Steve Woloshin (2011-01-18). Overdiagnosed: Making People Sick in the Pursuit of Health. Beacon Press. pp. 138–143. ISBN 9780807022009. Retrieved 7 October 2012.
- Sherman (2009). "Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers". Journal of Clinical Endocrinology & Metabolism 94 (5): 1493–1499. doi:10.1210/jc.2008-0923.
- Welch, H. Gilbert; Woloshin, Steve; Schwartz, Lisa A. (2011). Overdiagnosed: Making People Sick in the Pursuit of Health. [Malaysia?]: Beacon Press. pp. 61–34. ISBN 0-8070-2200-4.
- Hofman MS (2013). "Thyroid nodules: Time to stop over-reporting normal findings and update consensus guidelines". BMJ 347: f5742. doi:10.1136/bmj.f5742. PMID 24068719.
- "Thyroid Cancer". MedicineNet.com. Retrieved 26 October 2011.
- Numbers from EUROCARE, from Page 10 in: F. Grünwald; Biersack, H. J.; Grںunwald, F. (2005). Thyroid cancer. Berlin: Springer. ISBN 3-540-22309-6.
- "FDA approves new treatment for rare form of thyroid cancer". Retrieved 7 April 2011.
- cancer.org Thyroid Cancer By the American Cancer Society. In turn citing: AJCC Cancer Staging Manual (7th ed).
- Numbers from National Cancer Database in the US, from Page 10 in: F. Grünwald; Biersack, H. J.; Grںunwald, F. (2005). Thyroid cancer. Berlin: Springer. ISBN 3-540-22309-6. (Note:Book also states that the 14% 10-year survival for anaplastic thyroid cancer was overestimated)
- Rounded up to nearest natural number from 96.7% as given by eMedicine Thyroid, Papillary Carcinoma Author: Luigi Santacroce. Coauthors: Silvia Gagliardi and Andrew Scott Kennedy. Updated: Sep 28, 2010
- By 100% minus cause-specific mortality of 17% at 5 yr, as given by Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF (2005). "Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma". Journal of Clinical Endocrinology & Metabolism 90 (11): 6077–6084. doi:10.1210/jc.2005-0044. PMID 16091497.
- National Cancer Institute, Medullary Thyroid Cancer Last Modified: 12/22/2010
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.
- Santini F, Marzullo P, Rotondi M, Ceccarini G, Pagano L, Ippolito S, Chiovato L, Biondi B (October 2014). "Mechanisms in Endocrinology: The crosstalk between thyroid gland and adipose tissue: signal integration in health and disease". Eur J Endocrinol 171 (4): R137–52. doi:10.1530/eje-14-0067. PMID 25214234.
- "Thyroid cancer statistics". Cancer Research UK. Retrieved 28 October 2014.
- "Celebrities with Thyroid problems". Retrieved 2013-08-11.
- "Survivors". Retrieved 2013-08-11.
-  Thyroidcancer.support
- Media related to Thyroid cancer at Wikimedia Commons
- Thyroid cancer at DMOZ
- Cancer Management Handbook: Thyroid and Parathyroid Cancers
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Taskforce (2006).
- UK thyroid can
- International Thyroid Oncology Group (ITOG) A non-profit group devoted to performing clinical trials to advance cures for thyroid cancer.